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Introduction: Achievement of optimal vancomycin exposure is crucial to improve the management of patients
with life-threatening infections caused by susceptible Gram-positive bacteria and is of particular concern in patients with
augmented renal clearance (ARC). The aim of this study was to develop a dosing nomogram for the administration of
vancomycin by continuous infusion for the first 24 hours of therapy based on the measured urinary creatinine clearance
(8 h CLCR).
Methods: This single-center study included all critically ill patients treated with vancomycin over a 13-month period
(group 1), in which we retrospectively assessed the correlation between vancomycin clearance and 8 h CLCR. This data
was used to develop a formula for optimised drug dosing. The efficiency of this formula was prospectively evaluated in
a second cohort of 25 consecutive critically ill patients (group 2). Vancomycin serum concentrations between 20 to
30 mg/L were considered adequate. ARC was defined as 8 h CLCR more than 130 ml/min/1.73 m
2.
Results: The incidence of ARC was 36% (n = 29/79) and 40% (10/25) in group 1 (n = 79) and 2 (n = 25), respectively. The
mean serum vancomycin concentration on day 1 was 21.5 (6.4) and 24.5 (5.2) mg/L, for both groups respectively. On the
treatment day, vancomycin plasma clearance was 5.12 (1.9) L/h in group 1 and correlated significantly with the 8 h CLCR
(r2 = 0.66; P <0.001). The achievement of adequate vancomycin serum concentrations in group 2 was 84% (n = 21/25)
versus 51% (n = 40/79) – P <0.005.
Conclusions: This new vancomycin nomogram enabled the achievement of adequate serum concentrations in 84% of
the patients on the first day of treatment.Introduction
The emergence of multidrug-resistant bacteria has been
associated with the inappropriate use and the inadequate
dosing of antibiotics [1]. The EPIC II study showed that
51% of the patients admitted to ICU had infections and
that 71% of all patients were receiving antibiotics [2].
In addition, this study demonstrates that infection by
methicillin-resistant Staphylococcus aureus (MRSA) is
particularly problematic. Compared to methicillin-susceptible
S. aureus (MSSA), MRSA is independently associated
with an almost 50% higher likelihood of hospital death [3]* Correspondence: joaopedrobaptista@gmail.com
1Serviço de Medicina Intensiva, Centro Hospitalar e Universitário de Coimbra,
Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal
Full list of author information is available at the end of the article
© 2014 Baptista et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and has been considered as a serious threat by the Centers
for Disease Control and Prevention (CDC) [4]. Despite its
widespread use, vancomycin remains the first-line agent in
the treatment of patients with MRSA infection, including
those in the critical-care setting. In Portugal, MRSA preva-
lence is one of the highest in Europe and the emergence of
vancomycin-resistant enterococci and vancomycin-resistant
S. aureus is an area of particular concern [5,6].
Though there are limited data to support its routine
use in patient care [7], the administration of vancomycin by
continuous infusion (CI) has been used for the treatment of
critically ill septic patients, because of its practical
advantages: 1) rapid achievement of steady-state target
concentrations; 2) lower variability in drug exposure; 3)
simplicity of interpretation of therapeutic drug monitoringl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lower rates of nephrotoxicity, 6) lower costs and 7) lower
mortality [8-11]. However, achieving the desired serum
concentration can still be difficult in this group of patients
[11-14]. Amongst the several factors that contribute to the
difficulties in establishing adequate dosing regimens [15],
augmented renal clearance (ARC) is emerging as a new
and crucial factor, since vancomycin is predominantly elim-
inated by the kidneys [16,17]. ARC refers to an enhanced
elimination of circulating solute including drugs and is
defined as a creatinine clearance exceeding 130 ml/minute.
ARC appears to be quite common in sub-populations of
critically ill patients and can lead to very low concentrations
of renally cleared drugs like vancomycin.
The aim of this study was to develop a dosing nomogram
for the administration of vancomycin by CI for the first
24 h of therapy based on an 8-h measured urinary creatin-
ine clearance (8 h CLCR); and second, to evaluate its
efficiency in a separate cohort of critically ill septic patients.
Material and methods
Study design
This single-center study was conducted in a 20-bed
mixed ICU at the 1,375-bed Coimbra University Hospi-
tals (Portugal). Data were collected retrospectively over
a 13-month period from all consecutive, ventilated, adult
patients with severe sepsis or septic shock who started em-
pirical or directed treatment that included vancomycin
(group 1). The intravenous treatment protocol started with
a loading dose of vancomycin (Vancomicina Hikma®, Hikma
Farmacêutica, Terrugem, Sintra, Portugal) based on the
patient’s actual weight, of 1,000 mg (body weight ≤70 kg) or
1,500 mg (body weight >70 kg) over 1 to 2 h, followed by
CI (30 mg/kg/day). Daily TDM (between 7:00 and 7:30 am)
of serum vancomycin concentrations was performed, start-
ing the next day (day 1). Serum concentrations between 20
and 30 mg/L were considered adequate [16]. An increased
serum creatinine concentration >0.3 mg/dL on two or more
consecutive days and so-called red-man syndrome were
considered adverse effects related to vancomycin adminis-
tration. Ototoxicity evaluation was not feasible during the
study period. At Coimbra University Hospitals, S. aureus
shows no resistance to vancomycin (minimum inhibitory
concentration (MIC) ≤1 mg/L - European Committee on
Antimicrobial Susceptibility Testing (EUCAST)).
Height, weight, body mass index (BMI) and body
surface area (BSA) were measured. The DuBois and
DuBois formula was used to calculate BSA as follows:
BSA ¼ 0:007184  Height cmð Þð Þ0:725
 weight kgð Þð Þ0:425:
A daily 8 h CLCR was collected during the patient’s
ICU admission, between 23:00 h and 07:00 h, as part ofthe daily routine procedure in our unit. This measurement
used a standard urinary collection (via indwelling catheter)
for the 8-h period following measurement of creatinine
concentration in urine (u) and blood (s) for calculation of
8 h CLCR (ml/minute/1.73 m
2), according to the formula:
8hCLCR ¼ uCr=sCrð Þ  8hurinaryoutput=480ð Þ
 1:73=BSAð Þ
ð1Þ
Augmented renal clearance was defined as 8 h
CLCR >130 ml/minute/1.73 m
2. Exclusion criteria were the
following: 1) need for renal replacement therapy; 2) serum
creatinine concentration >1.3 mg/dL; 3) known chronic
kidney disease; 4) age under 18 years; 5) pregnancy, and 6)
ICU stay of less than 48 h. Using a previously described
methodology [17,18], we calculated the vancomycin plasma
clearance (CLvanco) according to the formula:
CLvanco L=hð Þ ¼ IR mg=hð Þ=Css mg=Lð Þ ð2Þ
Where IR represents infusion rate of vancomycin by
CI and and Css represents the vancomycin serum con-
centration at pseudo steady-state. Relationship between
CLvanco and 8 h CLCR was used to define a dosing
nomogram for vancomycin for different 8 h CLCR that
targets a target Css of 25 mg/L. The rationale behind the
choice of 25 mg/L as the ideal target was based on
current recommendations and on the pharmacokinetic/
pharmacodynamic (PK/PD) characteristics of vancomycin
[16,19]. The resultant dosing nomogram was then prospect-
ively applied for vancomycin dosing by CI in the ICU (after
adequate loading dose). Thereafter, we collected data on the
serum drug concentration on day 1 on the first 25 treated
critically ill septic patients (group 2). Vancomycin treat-
ment was initiated at the discretion of the ICU physician.
Inclusion criteria for the second cohort were as following:
1) evaluation of 8 h CLCR the day of initiation of
vancomycin; 2) stable renal function; 3) administration
of loading and maintenance dose per protocol, and
4) interval between loading dose and TDM for
vancomycin >12 h and <24 h.
This study was approved by the Human Research
Ethics Committee of Coimbra University Hospitals
(CHUC-114-13), which waived the need for informed
consent.
Statistical analysis
The results were analyzed with the SPSS software
package v.19.0 (SPSS Inc., Chicago, IL, USA) and with
MedCalc software v.9.3.8 for Windows (MedCalc Software,
Mariakerke, Belgium). Continuous variables are expressed
as mean (standard deviation) or median (interquartile
range) where applicable. Qualitative variables are presented
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variables were calculated using Fisher’s exact test. For sub-
group comparison of continuous data, the Student t-test
was used. Linear regression was employed for curve fitting.
A P-value of <0.05 was considered statistically significant.
Results
The main demographic characteristics of the patients
belonging to groups 1 and 2 (79 and 25 patients,
respectively) are shown in Table 1 and the dosing
characteristics and observed pharmacokinetics of
vancomycin treatment are described in Table 2. The
predominant foci of the infection were lung (63.2%),
skin and soft tissues (7.5%), bloodstream (6.3%) and
abdominal (6.3%). Globally, the frequency of achievement
of adequate vancomycin serum concentrations (20 to
30 mg/L) was 51% (n = 40/79) in group 1 versus 84%
(n = 21/25) in group 2 (P <0.005). Of note, the population
of group 1 showed a wide range of renal function, between
25 and 335 ml/minute/1.73 m2. The incidence of ARC in
group 1 was 36% (n = 29/79) and the CLvanco was 6.8 and
4.2 L/h in patients with and without ARC, respectively.
Within these 29 patients showing ARC, only 28%
achieved adequate vancomycin serum concentrations
(20 to 30 mg/L); 74% of the remaining 50 patients





Body surface area, m2
Body mass index, kg/m2
New simplified acute physiology score
8 h CLCR on day 1, mL/min/1.73 m
2
Baseline serum creatinine, mg/mL
Lowest serum creatinine, mg/mL*
Highest serum creatinine, mg/mL*
Patients with serum creatinine increase >0.3 mg/mL, number (%)*
Patients with ARC on day 1, number (%)
Mechanical ventilation on day 1, number (%)
Admission days




Quantitative variables were expressed as mean (standard deviation) or median (inte
renal clearance (ARC) defined as 8 h CLCR >130 mL/min/1.73 m
2; 8 h CLCR, 8-hour mCLvanco on day 1 in group 1 was significantly linearly
correlated (r2 = 0.66; P <0.001) (Figure 1).
The equation from the linear regression was as
follows:
CLvanco L=hð Þ ¼ 0:021x8hCLCR mL=minð Þ þ 2:3 ð3Þ
Using equation 3, a new equation was developed for
calculating a continuous infusion vancomycin dose per
day, considering 25 mg/L as the preferred target:
Vancomycindose g=dð Þ ¼ 0:021x8hCLCR þ 2:3ð Þ
 25 mg=Lð Þ  24=1000
¼ 0:021x8hCLCR þ 2:3ð Þ  0:6
ð4Þ
We then used equation 4 to develop a dosing nomogram
for vancomycin dosing in the first 24 h, after a loading dose
(Figure 2). As a result of the application of this nomogram
on group 2 (n = 25 patients), we observed that 21 (84%)
achieved serum concentrations between 20 and 30 mg/L
on day 1. Two patients (8%) exceeded these limits (34.3
and 33.7 mg/L) and another two patients did not meet the
target interval (16.8 and 16.7 mg/L). Of note, all the
patients with ARC belonging to group 2 were in the target
concentration range (n = 10/10), meaning that all theoup 1 (retrospective cohort) and group 2 (second cohort)
Group 1 Group 2 p
(79 patients) (25 patients)
52 (66.0) 17 (68.0) ns
57.8 (15.5) 59.9 (17.2) ns
77 (70-86) 75 (67.5-87.5) ns
1.87 (0.16) 1.86 (0.19) ns
28.1 (25.3-30.4) 25.7 (24.4-30.6) ns
39 (34-50) 43 (37-46) ns
125.1 (66.5) 120.5 (54.2) ns
0.68 (0.30) 0.68 (0.31) ns
0.57 (0.20) 0.60 (0.19) ns
0.73 (0.28) 0.81 (0.45) ns
5 (6.3) 1 (4.0) ns
29 (36.7) 10 (40.0) ns
79 (100) 25 (100) ns




rquartile range) when applied. *During the vancomycin treatment. Augmented
easured urinary creatinine clearance; ns, non significant.
Table 2 Dosing information and pharmacokinetics of vancomycin in the retrospective cohort (group 1) and in the
second cohort (group 2)
Group 1 Group 2
(79 patients) (25 patients)
Loading dose of vancomycin on day 0, mg 1000 (1000-1500) 1500 (1000-1500)
Loading dose of vancomycin on day 0, mg/kg 14.3 (12.8-17.6) 18.8 (16.7-21.4)
Perfusion dose of vancomycin on day 0, mg 1920 (1512-2400) 2072 (1750-2622)
Total dosing of vancomycin on day 0, mg 3160 (2520-3880) 3584 (2976-4138)
Time interval (h) between vancomycin perfusion and TDM 18 (17-27) 18 (17-19)
Serum vancomycin concentration on day 1, mg/L 20.6 (16.7-26) 24.5 (22.2-27.4)
Clearance of vancomycin on day 1, L/h 5.1 (1.9) NC
Values are expressed as median and interquartile range [Q25-Q75] except for Clearance of vancomycin on day 1 (mean and standard deviation).
TDM, therapeutic drug monitoring; day 0, the day before day 1, corresponding to the day of the administration of vancomycin; NC, not calculated.
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(4/15, 26.6%). The observed vancomycin serum concen-
trations within the 25 patients, and the respective visual
interrelation with the target interval (20 to 30 mg/L) and
preferred target concentration (25 mg/L) is showed in the
Figure 3. With the exception of one patient who had an
increase of over 0.3 mg/dL of serum creatinine con-
centration in two consecutive days without needing treat-
ment interruption (1/25, 4.0%), no clinical or laboratory
vancomycin-related side effects were noted during the
period of treatment at the ICU within group 2. On
the other hand, the incidence of nephrotoxicity during






















R2 Linear = 0,663
Figure 1 Linear correlation between 8-hour measured urinary creatin
(79 patients). R2 = 0.663, P <0.001.Discussion
Our results show that in a broad population of adult
ICU patients treated with continuously infused vanco-
mycin, the use of a dosing nomogram significantly
increased the achievement of therapeutic concentrations
in the first 24 h of treatment, particularly in the patients
exhibiting ARC. Application of this nomogram was found
to be easy, user-friendly and effective. The nomogram
requires the availability of an 8 h CLCR and vancomycin
serum concentration monitoring, which is not avail-
able in all ICUs, but these results demonstrate how
beneficial such tests can be to ensure more accurate
antibiotic dosing.)
252015
ine clearance and vancomycin clearance on day 1 in group 1
Figure 2 Nomogram for calculation of the daily vancomycin dosage (g/24 h) administered by continuous infusion required for
achievement of target drug concentration (25 mg/L) based on 8-hour measured urinary creatinine clearance. 8 h CLCR = 8-hour
measured urinary creatinine clearance.
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predominantly excreted unchanged in urine by glomerular
filtration and as such, kidney function is a determinant
factor of vancomycin pharmacokinetics and dosing. The
best measure of kidney function is the glomerular
filtration rate (GFR). Urinary creatinine clearance seems
to be the best clinical surrogate of renal function, taking
into account its applicability at the bedside, its reliability
and the negligible costs associated, provided that clinicians
are aware of its limitations [20-22]. Estimates of GFR
using equations based on serum creatinine concentrations
are flawed in the critically ill patient [21,23]. Taking all of
this information together, the measurement of the
renal clearance of creatinine in this setting could be
used, from a clinical point of view, as the single most
accessible parameter allowing appraisal of pharmacokinetic
characteristics of the critically ill patient.
Clinicians are used to adjusting the dosing of antibiotics
according to acute or chronic renal failure, however the
adjustment to elevated function of the kidneys is considered
to be quite rare, and there are no recommendations on this
clinical issue. Moreover, the incidence of ARC (here defined
as CLCR >130 ml/minute/1.73 m
2) is probably high and
ubiquitous in every ICU with an underestimated incidence
[24]. Indeed ARC is being increasingly described, with
previously reported rates, varying widely between 18%to as high as 57% in critically ill patients without
renal dysfunction [23,24].
In the context of severe infection, a major consequence
of ARC is the high renal clearance of hydrophilic
antibiotics leading to a risk of inducing sub-therapeutic
concentrations, therapeutic failure, emergence of multi-
resistant bacterial strains, and even potentially increased
mortality [25]. To date, different antibiotics have been
studied in the presence of ARC and these reports
have shown a strong association between ARC and
sub-therapeutic concentrations [12,26,27]. Importantly
for vancomycin, low serum concentrations are associated
with decreases in susceptibility and in treatment failure of
patients with MRSA infections [28]. A recent large-scale
multicentre point-prevalence study revealed that a
substantial proportion of critically ill patients treated
with vancomycin did not achieve the target vancomycin
concentration and showed high variability in pharmacokin-
etics parameters, supporting a re-evaluation of vancomycin
dosing recommendations in this particular setting [29].
Furthermore, a recent consensus review recommended
more aggressive vancomycin dosing to ensure achievement
of the pharmacodynamic index associated with efficacy
[16]. Though vancomycin is widely used in the ICU, there
are relatively few studies focused on the early optimization
of serum concentrations where CI is the prescribed mode
Figure 3 Distribution of the serum vancomycin concentrations within the 25 patients belonging to group 2. The grey area represents the
target interval for serum vancomycin on the day 1 of treatment (serum concentrations between 20 and 30 mg/L).
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among these used measured renal clearance of creatinine
[32-34], three used mathematical estimates of renal
function [18,31,35] and one study did not provide this
information [30]. Among those studies evaluating the
serum vancomycin concentration on day 1 or day 2, the
achievement of target concentrations of 20 to 30 mg/L
ranged between 48 and 52% [30,32].
A recent study described a new regimen for CI of
vancomycin during continuous renal replacement therapy,
which allowed the achievement of target drug concentra-
tions in 63% of patients at 24 h [36]. Our study, using a
dosing regimen guided by a dosing nomogram that is based
on the 8 h CLCR and after an adequate loading dose,
permitted us to reach the target drug concentration in most
patients on day 1 (n = 21/25, 84%), providing optimal
and early antibiotic exposure in the septic patient, with
negligible secondary effects (only one patient with a
minor increase in serum creatinine concentration,
without evolution to renal failure or need for interruption
of the treatment). Roberts et al. conducted a population
pharmacokinetic analysis of vancomycin CI in a large
cohort of critically ill patients, using a Monte Carlo dose
simulation for different total body weight, for different
creatinine clearances and for different weight-based
dosing vancomycin CI regimens [35]. The authors foundthat higher-than-recommended loading and daily
doses of vancomycin seem to be necessary to rapidly
achieve therapeutic serum concentrations in these
patients. In addition, they state that a patient with a CLCR
of 100 ml/minute/1.73 m2 would require at least 35 mg/kg
per day by CI to maintain target concentrations. Curiously,
when we use the average weight of our 25 patients
belonging to group 2 (75 kg), we found very similar
results: 2.625 mg versus 2.600 mg (according to Table 3) in
a period of 24 h, respectively. Both approaches seem to
exhibit some complementarity: a retrospective development
of a model and, on the other hand, a clinical prospective
validation of a nomogram, respectively.
To the best of our knowledge, the study by Pea et al. is
the only to provide and validate two user-friendly dosing
nomograms for the treatment of critical ill patients
with vancomycin by CI [18]. They described a significant
correlation between CLvanco and creatinine clearance
(r2 = 0.56, P <0.001) and between the observed and the
predicted serum drug concentration (r2 = 0.64, P <0.001),
confirming the dependency of vancomycin elimination on
the renal function. However, as acknowledged by the
authors, the renal performance was evaluated by the
Cockroft-Gault formula, which is a limitation of the study
[21,23]. Of interest and despite this, when we created a
new dosing nomogram based on the formula described by
Table 3 Daily vancomycin dosage administered by
continuous infusion for achievement of target drug
concentration (25 mg/L) for different values of creatinine
clearance using two different nomograms
Creatinine clearance,
mL/minute
Vancomycin dosing, g/24 h
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in our study (25 mg/L), we obtained similar results for the
calculation of the daily vancomycin dosage by CI to
achieve target drug concentration (Table 3), confirming in
two independent studies the need for a higher dosage
to achieve adequate concentrations in the first 24 h
of treatment with vancomycin by CI. The similar
methodology applied in both studies, similar populations,
exclusion of patients with prolonged ICU admission,
and choice of the Cockroft-Gault formula by Pea and
coworkers (showing higher accuracy when compared
with other estimates of renal creatinine clearance
[23]) may be possible explanations for the similarities
between the two nomograms. On the other hand, the lower
incidence of ARC in both cohorts (approximately 15%)
when compared to those in our study (36.7 and 40.0% in
group 1 and 2, respectively) and the recent literature
describing lower accuracy of Cockroft-Gault estimates in
both extremes of the normal range of 8 h CLCR [23,37]
may be possible explanations for the lower agreement
between the two nomograms, particularly when considering
low and very high values of 8 h CLCR.
Altogether, our study shows that it is possible to increase
the likelihood of target attainment in the first 24 h of
treatment with vancomycin, with potential benefits
including better outcome and reduction of the develop-
ment of bacterial resistance. Our study strengths lie in
the considerable number of patients included in the retro-
spective cohort, the significant correlation obtained
between measured 8 h CLCR and CLvanco (r
2 = 0.66,
P <0.001), and the wide range of 8 h CLCR exhibited bythese patients (25 to 335 ml/minute/1.73 m2). Therefore,
this study is based on a representative cohort of septic
critically ill patients, making it applicable in various
levels of renal function, including patients with ARC - a
sub-group with particular risk of under-treatment with
vancomycin [12].
However, some limitations should be acknowledged. First,
this was a single-center study, and therefore an extrapola-
tion of the findings to other settings must be done with cau-
tion. Second, the second cohort (group 2) was smaller,
giving less certainty to our conclusions. Third, 8 h CLCR
cannot be accepted as a gold-standard method to assess
kidney function: its determination requires creatinine con-
centrations to be at steady-state, which is a rarely reached
condition in critically ill patients. Finally, pharmacokinetic
studies require a constant physiological status, leading us
again to the absence of physiological stability in the critical-
care setting. In addition, it is possible that not all patients
were at actual steady-state, given that 11% of patients in
group 1 had an interval between commencement of vanco-
mycin infusion and sampling for TDM less than 16 h.
Conclusions
A novel and easy-to-use vancomycin dosing nomogram
for the first 24 h of treatment, based on the 8-h renal
clearance of creatinine has been developed and prospect-
ively shown to be effective in septic and critically ill pa-
tients at a teaching hospital.
Key messages
 Augmented renal clearance appears to be quite
common in sub-populations of critically ill patients
and can lead to very low serum concentrations of
vancomycin on the first day of treatment
 Clinicians are used to adjusting the dosing of
antibiotics according to renal failure; however the
adjustment to elevated function of the kidneys appears
important to ensure target concentrations are achieved
 This study prospectively validated a new
vancomycin dosing nomogram based on the 8-hours
renal clearance of creatinine and demonstrated that
it is possible to increase the likelihood of target
attainment in the first 24 h of treatment, particularly
in patients with augmented renal clearance
 Adequate serum concentrations of vancomycin
should be confirmed with therapeutic drug
monitoring, particularly in patients with extreme
renal function alteration
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